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The central nervous system (CNS) has the highest concentration of lipids in the
organism after adipose tissue. Among these lipids, the brain is particularly enriched
with polyunsaturated fatty acids (PUFAs) represented by the omega-6 (ω6) and omega-
3 (ω3) series. These PUFAs include arachidonic acid (AA) and docosahexaenoic acid
(DHA), respectively. PUFAs have received substantial attention as being relevant to many
brain diseases, including anxiety and depression. This review addresses an important
question in the area of nutritional neuroscience regarding the importance of ω3 PUFAs
in the prevention and/or treatment of neuropsychiatric diseases, mainly depression and
anxiety. In particular, it focuses on clinical and experimental data linking dietary intake of
ω3 PUFAs and depression or anxiety. In particular, we will discuss recent experimental
data highlighting how ω3 PUFAs can modulate neurobiological processes involved
in the pathophysiology of anxiety and depression. Potential mechanisms involved in
the neuroprotective and corrective activity of ω3 PUFAs in the brain are discussed,
in particular the sensing activity of free fatty acid receptors and the activity of the
PUFAs-derived endocannabinoid system and the hypothalamic–pituitary–adrenal axis.
Keywords: omega-3 fatty acid, endocannabinoids, HPA axis, nutrient sensing, mood disorders, anxiety,
depression, DHA
INTRODUCTION
Since the discovery of omega-3 (ω3) PUFAs in 1929 by George Burr and Mildred Burr (Burr
and Burr, 1929; Spector and Kim, 2015), research on ω3 PUFAs became an appealing topic
ranging from their role in cardiovascular risk to more recently neuropsychiatric pathologies such
as depression and anxiety, cognitive decline or neurodegenerative diseases (Bazinet and Layé,
2014; Joffre et al., 2014; Coulombe et al., 2017). The relevance of lipids in brain function is
illustrated by the fact that the CNS has the highest concentration of lipids in the organism after the
Abbreviations: 2-AG, 2-arachidonoylglycerol; AA, arachidonic acid; AC, adenylyl cyclase; AEA, ethanolamides
anandamide; ALA, alpha-linolenic acid; CA1, cornu ammonis 1; cAMP, cyclic adenosine monophosphate; CB1R,
cannabinoid receptor 1; CNS, central nervous system; COX, cyclooxygenase; CRH, corticotrophin-releasing hormone;
CSDS, chronic social defeat stress; CYP450, cytochrome P450; DHA, docosahexaenoic acid; DHEA, docosahexaenoyl
ethanolamide; DPA, docosapentaenoic acid; eCB, endocannabinoid; EPA, eicosapentaenoic acid; FADS, fatty acid desaturases;
FFAR, free fatty acid receptors; FST, forced swimming test; GABA, gamma-aminobutyric acid; GPCR, G-protein-
coupled receptor; GPR120, G-protein-coupled receptor 120; GPR40, G-protein-coupled receptor 40; GR, glucocorticoid
receptor; HPA, hypothalamic–pituitary–adrenal; IL, interleukin; LA, linoleic acid; LC, long chain; LOX, lipoxygenases; LPS,
lipopolysaccharide; NAc, nucleus accumbens; PFC, prefrontal cortex; PPAR, peroxisome proliferator-activated receptor;
PTSD, post-traumatic stress disorders; PUFAS, polyunsaturated fatty acids; RXR, retinoid X receptor; SPMs, specialized pro-
resolving lipid mediators; SSRI, selective serotonin reuptake inhibitor; TNFα, tumor necrosis factor α; WHO, World Health
Organization.
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adipose tissue (50–60% of the dry weight of the brain; Sastry,
1985). Among these lipids, the brain is particularly greedy for
PUFAs from the ω6 and ω3 PUFAs families, in particular the LC
PUFA (AA, 20:4n-6) and (DHA, 22:6n-3), respectively (Sastry,
1985). In the Human brain, DHA accounts for 10 to 15% of
the total fatty acids (saturated, monounsaturated and PUFAs)
in both males and females (McNamara et al., 2007, 2008b).
This makes PUFAs indispensable to the normal development
and function of the CNS (Makrides and Gibson, 2000; Innis,
2007; Bazinet and Layé, 2014). One hypothesis explaining this
abundance in brain tissue is that Homo sapiens in Paleolithic
settled around the lakes and seas where access to foods rich in
ω3 PUFAs is easy (Bradbury, 2011). It is generally considered
that humans evolved on a diet with a ratio of ω6 to ω3 PUFAs
equal approximately to 1. During the industrial era, the rapid
expansion of Western countries has been associated with drastic
changes in the ω6/ω3 PUFAs content of the diet. This is reflected
in large quantities of ω6 PUFA-containing foods and smaller
amounts of ω3 PUFA-rich foods leading to Western diet being
typically poor in ω3 PUFAs. In addition, the intake of saturated
fats from lard and butter has been replaced by plant-based PUFAs
based on recommendations from health agencies (Gibson et al.,
2011). As a result, the use of oils such as sunflower oil which are
mostly high in (LA, the precursor of AA) and low in a-linolenic
acid (ALA, the precursor of DHA) leads to a marked increase
in LA intake. In mammals, LA and ALA cannot be synthesized
de novo and need to be provided through the diet (Simopoulos,
1991; Gibson and Makrides, 2001). These essential PUFAs are
metabolized into LC PUFAs using the same enzymatic pathway,
meaning that LA and ALA are in competition for endogenous
conversion to their respective LC forms AA, and DHA (Figure 1)
but also for their entry into the brain (Bazinet and Layé, 2014).
Of importance, ALA bioconversion into DHA through several
cycles of elongation (ELOVLs) and desaturation (15 and 16
desaturases) is in the range of 0.05% (Burdge et al., 2003) to
4% (Emken et al., 1994) and might not be sufficient to cover
brain needs. This led to the recommendation of dietary intake
of oily fish rich in the LC ω3 PUFAs DHA and EPA (Tejera et al.,
2016). Overall, western diets which are rich in LA (coming from
vegetable oils rich in LA) and poor in ALA and DHA (coming
from fat fish, sea food or certain algae) have created “a conditional
essentiality for ω3 PUFAs” as previously described by Cunnane
(2003) and Gibson et al. (2011). Indeed, the amount of LC ω3
PUFAs needed to compensate this lack in western diet is likely
to increase, which is not sustainable in the actual context of fish
stock decline (Fernandes and Cook, 2013).
The reduced dietary supply of ω3 PUFAs to the brain
is associated with many brain diseases, including depression
and anxiety disorders (see review from Müller et al., 2015).
Epidemiological studies have linked low ω3 PUFAs dietary intake
with the prevalence of depression in the general population
(Hibbeln, 1998). Clinical studies further revealed that subjects
diagnosed with depression or anxiety display significant lower
levels of ω3 PUFAs and higher ratio of ω6 to ω3 PUFAs in
the blood and in the brain (Green et al., 2006; McNamara and
Liu, 2011; Parletta et al., 2016). Supporting clinical observations,
preclinical studies conducted in rodents showed that ω3 PUFA
deficient diet consumption induces depressive- and anxiety-
like symptoms as well as abnormal social behavior in adult
offspring (Lafourcade et al., 2011; Larrieu et al., 2012, 2014,
2015; Bondi et al., 2014). Importantly, the use of dietary
animal models has been crucial to study the neurobiological
mechanisms underlying the alteration of emotional behaviors
following decreased bioavailability of ω3 PUFAs in the brain. In
this review, we first discuss clinical and pre-clinical evidence of
the importance of ω3 PUFAs in anxiety and depressive disorders
as well as the rationale for evaluating baseline levels of ω3
PUFAs prior to starting nutritional intervention studies. Then we
describe mechanisms linking ω3 PUFAs and emotional behaviors
disturbance, especially the sensing activity of FFAR, the eCB
system, glucocorticoids as well as neuroinflammatory pathways.
THE ROLE OF ω3 PUFAs IN
DEPRESSION AND ANXIETY
DISORDERS
Clinical and Epidemiological Evidence
Linking ω3 PUFAs, Depression and
Anxiety
Several clinical and epidemiological studies highlighted the link
between mood disorders and blood and/or cellular membrane
PUFAs content (reviewed in Müller et al., 2015). These
observations led to the “phospholipids hypothesis” according to
which PUFAs are possible aetiological factors in the development
FIGURE 1 | Long-chain PUFAs synthesis. Essential fatty acids precursors of n-6 and n-3 PUFAs are provided by food. Once in the livers, they are metabolized into
long-chain PUFAs using a series of desaturations and elongation machinery. The newly synthetized long-chain n-6 PUFAs are AA (20:4n-6) and DPA (22:5n-6) and
the long-chain n-3 PUFAs are DHA (22:6n-3) and DPA (22:5n-3).
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of depressive disorders (Hibbeln and Salem, 1995). Indeed,
subjects diagnosed for anxiety and depressive disorders show
lower ω3 PUFAs and higher ratio of ω6 to ω3 PUFAs in their
blood and brains compared to healthy subjects matching for
age and sex (Adams et al., 1996; Maes et al., 1996; Edwards
et al., 1998a,b; Tiemeier et al., 2003; Frasure-Smith et al., 2004;
Green et al., 2006; McNamara et al., 2007; McNamara and Liu,
2011; Parletta et al., 2016). EPA (20:5 n-3) concentration (Adams
et al., 1996; Green et al., 2006; Liu et al., 2013) as well as DHA
concentration (Edwards et al., 1998a; Frasure-Smith et al., 2004;
Green et al., 2006; McNamara and Liu, 2011; Liu et al., 2013;
Otoki et al., 2017) are decreased in the membrane of erythrocytes
and in the plasma of patients suffering from unipolar depression,
seasonal winter affective disorder or social anxiety disorders
(Adams et al., 1996; Green et al., 2006). A recent study showed
that the AA:EPA ratio in the blood is positively correlated with
illness duration in patients diagnosed with major depression
(Scola et al., 2018). A meta-analysis work from Lin et al. (2010)
supports these observations by showing significant low levels of
EPA, DHA, and total ω3 PUFAs among 3,318 depressed patients.
In some of these studies, the severity of the depressive and
anxious symptoms is negatively correlated with the concentration
of the total ω3 PUFA levels in the blood (Adams et al., 1996;
Maes et al., 1996; Edwards et al., 1998a; Green et al., 2006;
Liu et al., 2013). Post-mortem studies report reduced levels of
DHA in the PFC of patients diagnosed with major depression,
bipolar disorders or committing suicide (McNamara et al., 2007,
2008a, 2013). In pregnant women, for whom the risk of ω3
PUFAs deficiency is relatively high as they provide DHA to the
fetus, nearly 10% experience post-partum depression (Markhus
et al., 2013). Yet, no clear consensus exist as to whether low ω3
PUFAs and high ω6 PUFA levels in the blood are linked to the
development of post-partum depression (Hibbeln, 2002; Parker
et al., 2015). These observations are not limited to depression as
decreased ω3 PUFAs (DHA) levels in erythrocytes and PFC have
also been found in patients suffering from PTSD (de Vries et al.,
2016). As decreased ω3 PUFAs status is associated with several
forms of depression and stress disorders, the understanding of
the origin (dietary or genetic) of the decreased bioavailability of
DHA or EPA is of high interest.
The rationale for identifying baseline nutritional ω3 PUFAs
status comes from one hypothesis advanced by researchers
that weak food supply in ω3 PUFAs might be a risk factor
of the development of depression. As fish is the main source
of LC ω3 PUFAs, several epidemiological studies investigating
putative associations between major depressive disorder and
fish consumption were conducted in various countries (Finland,
New Zealand, France, Northern Ireland, Norway or Netherlands)
(Tanskanen et al., 2001; Silvers and Scott, 2002; Timonen
et al., 2004; Barberger-Gateau et al., 2005; Kamphuis et al.,
2006; Appleton et al., 2007; Raeder et al., 2007; Colangelo
et al., 2009). Subjects having low fish consumption (lower
than once per week, including seafood) present high scores
of depression (Timonen et al., 2004; Barberger-Gateau et al.,
2005). A transnational ecological study conducted on a large
cohort including individuals from different countries highlighted
a strong negative correlation between fish consumption and
the prevalence of depression (Hibbeln, 1998). Indeed, this
epidemiological study of great width (170,000 individuals)
revealed that individuals from Asian countries like Japan, Korea,
and Taiwan, who are the biggest fish consumers, suffer relatively
little from major depression. This observation can appear
counterintuitive as Japan experiences a high rate of suicide while
the depression rate is thought very low (WHO, 2015). Such a high
rate of suicide has been associated to cultural factors (idealization
of suicide, acceptability, etc.) including aging society (Saito et al.,
2013), divorce and unemployment (Yamauchi et al., 2013). On
the contrary, Western countries like New Zealand, Canada,
United States, Germany, or France are part of the countries that
consume less fish with high prevalence to develop depression.
These data suggest that fish consumption is conversely correlated
with the development of depression.
To PUFA dietary intake consideration in decreasing ω3
PUFAs bioavailability in depression, one must add the genetic
variation of the FADS, an enzyme which converts PUFA
precursors into LC-PUFAs (EPA, DHA, and AA) (Koletzko et al.,
2011; Mathias et al., 2014; Park et al., 2015). Indeed, inter-
individual variability in red blood cells DHA and AA levels
is explained by FADS polygenes (71 and 53%, respectively)
(Lemaitre et al., 2008). FADS genotypes influence DHA amounts
in red blood cells of pregnant women independently of dietary
effects (Koletzko et al., 2011). Children carrying FADS minor
allele have lower DHA levels in erythrocyte, with no behavioral
outcomes (Jensen et al., 2014). However, the link between FADS
haplotype and the risk of developing neuropsychiatric disorders
(schizophrenia or depression) is weak (Fallin et al., 2004;
Schizophrenia Psychiatric Genome-Wide Association Study
(GWAS) Consortium, 2011). A study conducted in patients with
major depression found no association between FADS single
nucleotide polymorphisms and major depression (Sublette et al.,
2016). Recently, a study suggested that genetic variation in the
FADS gene influences the ω6/ω3 PUFAs ratio which appears to
be associated with major depression (Cribb et al., 2017). To our
knowledge, no study has so far linked brain DHA level to FADS
genotype. Overall, in addition to dietary composition of PUFAs,
FADS genetic variation should be considered in the LC-PUFAs
status and the pathophysiology of depression and stress.
Taken together, these clinical observations raise a crucial
question: Is there a causal link between the contents of ω3
PUFAs in the blood/brain and depressive/anxiety disorders? If
so, are the low levels of ω3 PUFAs the cause or the consequence
of these affective disorders? These relations of causalities were
approached by nutritional interventions in Humans which are
the object of the following section, first in depression, then in
PTSD and stress disorders.
Dietary ω3 PUFAs Supplementation,
Depression, and PTSD in Humans
The results from LC ω3 PUFA nutritional interventions carried
out among patients with depressive disorders are heterogeneous
as recently reviewed elsewhere (Bozzatello et al., 2016; Saunders
et al., 2016). Some studies conducted on patients suffering
from major depression without an antidepressant treatment
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do not show significant effects of ω3 PUFAs supplementation
(Marangell et al., 2003; Freeman et al., 2008; Rees et al., 2008;
Mischoulon et al., 2015), whereas others reveal a beneficial
effect (Su et al., 2003; Nemets et al., 2006; Jazayeri et al., 2008).
A 16-week dietary supplementation with EPA + DHA did not
prevent maternal depressive symptoms (Vaz et al., 2017). These
discrepancies are reflected by meta-analysis. Indeed, some found
that EPA and DHA can reduce depressive symptoms (Kraguljac
et al., 2009; Appleton et al., 2010; Sublette et al., 2011; Grosso
et al., 2014) while other found no effect (Appleton et al., 2015).
Mixed results of clinical trials could be attributed not only to the
heterogeneity in clinical trials and design, but also to the quantity
and quality of the PUFA used, including the EPA:DHA ratio,
trial duration, the type of placebo (PUFA or other fatty acids)
and to the concomitant use of medication and baseline symptom
severity. Recently, EPA, rather than DHA, has been suggested to
mediate the beneficial effect of ω3 PUFAs supplementation in
patients diagnosed with major depression DHA (Martins, 2009;
Martins et al., 2012; Grosso et al., 2014; Hallahan et al., 2016).
Indeed, several studies using ethyl-EPA (from 1 to 2 g/day)
reported a beneficial effect in patients with major depression
and resistant to anti-depressant (Peet and Horrobin, 2002) or
recurrent unipolar depression (Nemets et al., 2002). In addition,
EPA-rich formulation with no DHA is more effective than DHA-
rich supplements in major depression (Sublette et al., 2011).
A meta-analysis aiming at investigating the beneficial role of EPA
or DHA supplementation in major depressive disorder found
that EPA is more effective than DHA (Grosso et al., 2014). The
beneficial effect of EPA has been recently corroborated by a
new meta-analysis (Mocking et al., 2016). EPA efficiency could
be linked to its conversion into DHA by elongase leading to
increased DHA brain bioavailability and decreased LC ω6 PUFAs
production (Ganança et al., 2017). Indeed, as the conversion
of EPA into DHA compete with the production of n-6 DPA
from AA by using the same enzymatic pathway (i.e., FADS and
elongases), the supplementation of EPA can simultaneously lead
to an increase in DHA and a decrease in n-6 DPA levels that
can subsequently improve mood. However, further studies with
larger and more homogeneous samples are required to confirm
these effects.
In addition, it has been suggested that depressive patients
who display low levels of ω3 PUFAs may rather benefit of the
LC ω3 PUFAs supplementation (Carney et al., 2016; Messamore
and McNamara, 2016). Despite recent advances in understanding
the pathophysiology of major depression, approximately 30% of
patients remain refractory to multistep antidepressant treatments
(Rush et al., 2006a,b). One explanation of this finding could come
from individual differences in baseline levels of ω3 PUFAs. To
support this idea, a study recently showed that high baseline
levels of EPA and DHA in red blood cells of depressive patients
predict favorable depression outcomes in patients receiving ω3
PUFAs supplements (Carney et al., 2016). In addition, among
patients treated but resistant to antidepressants such as the (SSRI;
e.g., Fluoxetine, Paroxetine), the severity of the symptoms of
depression decreased in the group supplemented in ω3 PUFAs
(Nemets et al., 2002; Peet and Horrobin, 2002; Su et al., 2003;
Jazayeri et al., 2008; Gertsik et al., 2012; Zimmer et al., 2013;
McNamara et al., 2014; Mocking et al., 2016). This strategy can
be highly relevant as resistance to treatment is observed in a large
proportion of patients (40%) (Brunoni et al., 2009; Shelton et al.,
2010) and it suggests that dietary ω3 PUFA intake may improve
antidepressant response.
ω3 PUFAs dietary supplementation has also been used in
stress disorders. Stress is a well-known major risk factor for
the development of depression or PTSD. One study aimed
at investigating the effect of ω3 PUFAs supplementation in
chronically work-stressed individuals and found no significant
treatment effect for EPA after 12 weeks of supplementation
on the Perceived Stress Scale scores (Bradbury et al., 2017).
On the contrary, a placebo-controlled trial of ω3 PUFAs
supplements in patients suffering from PTSD revealed that EPA
but not DHA (Matsuoka et al., 2015) levels were inversely
correlated with PTSD severity suggesting the potential efficacy
of EPA rather than DHA for minimizing PTSD symptoms
(Matsuoka et al., 2016). Regarding ω3 PUFAs supplementation
in the prevention of anxiety, a study conducted by Yehuda
et al. (2005) has investigated whether administration of a
cocktail of ω3 PUFAs (90 mg of ALA/day) and ω6 PUFAs
(360 mg of LA/day) over 3 weeks in students could improve
anxiety induced by the university examinations. These authors
highlighted an improvement of several symptoms (appetite,
mood, concentration, and fatigue) compared to the placebo
group. These improvements are associated with a decreased
level of salivary cortisol (Yehuda et al., 2005). Despite the low
dose of ALA used in this study (90 mg/day) as compared to
nutritional intake in the general population (1–2 g/day), this 10%
increase was sufficient to improve symptoms. In addition, ALA
conversion in EPA is determined by the amount of ALA in the
diet (i.e., higher in the plasma phospholipid pool when ALA is
low) (Goyens et al., 2006). Thus, the effectiveness of ALA in
Yehuda et al.’s (2005) study could be linked to EPA. Moreover,
students having received a supplementation with DHA and EPA
during 12 weeks present a reduction of 20% of anxiety symptoms
compared to the students treated with a placebo (Kiecolt-Glaser
et al., 2011). In students treated with ω3 PUFAs supplementation,
an increase in plasma concentration of DHA and EPA were
observed as of the third week of treatment. Lastly, the increase
in DHA and EPA was negatively correlated with a reduction in
anxiety symptoms.
In conclusion, these observations further support the role of
PUFAs metabolism as an important mechanism in depression
and anxiety disorders treatment. This brings new insight to
personalized PUFAs formulation as a novel adjunctive treatment
for patients with mood and anxiety disorders.
Pre-clinical Studies Linking ω3 PUFAs
and Emotional Behavior
To better understand whether the modifications of nutritional
ω6/ ω3 PUFA ratio could affect brain function and behavior,
studies have been carried out in animals (rodents, monkeys, and
pigs) subjected to diets in which PUFAs contents are controlled
during one or several generations (de la Presa Owens and Innis,
1999; Clouard et al., 2015). Numerous studies have shown that in
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animal models of nutritional ω3 PUFA deprivation, brain DHA
levels were decreased while AA levels were increased in several
brain areas leading to an imbalance between ω6 and ω3 PUFAs
in the ω3 PUFAs deficient mouse brain (Delion et al., 1994;
Francès et al., 1995; Favrelière et al., 1998; Carrié et al., 2000b;
McNamara and Carlson, 2006; Lafourcade et al., 2011; Larrieu
et al., 2012). Nutritional ω3 PUFAs deficiency-induced reduction
of brain DHA levels has been associated with the development
of depression-like behavior (Carrié et al., 2000a; Takeuchi et al.,
2003; DeMar et al., 2006; Fedorova and Salem, 2006; Lafourcade
et al., 2011; Larrieu et al., 2012, 2014, 2015; Bondi et al., 2014;
Morgese et al., 2016; Manduca et al., 2017). By submitting mice
to one generation dietary ω3 PUFAs deficiency, we found that ω3
PUFAs deficient diet alone disturbed social behavior as well as
increased anxiety- and depression-related behavior in an open-
field and FSTs, respectively (Lafourcade et al., 2011; Larrieu et al.,
2012, 2014, 2015). Some studies conducted in rats indicate that
the time of immobility in the FST was increased by ω3 PUFAs
deficiency (DeMar et al., 2006; Morgese et al., 2016) and reduced
by ω3 PUFAs supplementation with fish oil (Naliwaiko et al.,
2004; Carlezon et al., 2005; Huang et al., 2008). In addition,
the level of DHA in rat whole brains is negatively correlated
with the time spent immobile during the FST, a behavioral test
used for evaluating the efficacy of compounds rendering or
preventing depressive-like states. Interestingly, similar behavioral
impairments (e.g., anxiety-like behavior and social interaction)
occur in mice after exposure to CSDS, a well-characterized
preclinical model of anxiety and depression (Golden et al., 2011;
Bosch-Bouju et al., 2016; Larrieu et al., 2017). This model presents
strong face validity, as social defeat (e.g., bullying) is a major
risk factor to developing depression in humans. One cardinal
feature of CSDS is that mice experiencing this chronic stress
develop a long-lasting (more than 1 month) aversion to social
interaction as well as anhedonia, which can be normalized after
chronic (28 days post-CSDS), but not acute administration of
antidepressant (Berton et al., 2006; Krishnan et al., 2007) as
observed in humans. By comparing the effects of dietary ω3
PUFAs deficiency to those of CSDS on emotional behavior,
We found that mice fed with a diet deficient in ω3 PUFAs
exhibited behavioral changes and neuronal atrophy profile that
resemble those of mice exposed to CSDS (Larrieu et al., 2014).
Interestingly, behavioral alterations can be reversed after chronic
ω3 PUFAs supplementation. As such, increased anxiety- and
depressive-like behavior after chronic stress is normalized after






Numerous epidemiological, clinical, and preclinical studies
demonstrated the key role of nutritional ω3 PUFAs in depression
and anxiety disorders. In recent years, emphasis was made
on identifying molecular and cellular mechanisms by which
ω3 PUFAs modulate brain function. ω3 PUFAs and their
metabolites are well known to play an important role as
signaling molecules that regulate inflammation (Serhan, 2014)
and neuroinflammation (recently reviewed in Layé et al., 2018).
They also contribute to signal transduction between neurons or
neurons and glial cells. Here, we will focus on DHA, the most
aggregated fatty acid in the brain while EPA is rapidly b-oxidized
and poorly accumulated (Chen and Bazinet, 2015). As DHA is
poorly synthesized de novo, its brain levels depend on both the
dietary supply and blood level bioavailability (Bazinet and Layé,
2014; Lacombe et al., 2018). Once free DHA has entered the brain,
it is esterified at membrane phospholipids (both in neurons and
glial cells). However, upon neuronal stimulation, injury or stress,
DHA is released from phospholipids and can either activate
specific receptors or be metabolized into specific derivatives, such
as eCBs or oxylipins which regulate specific pathways important
to neurotransmission or neuroinflammation (Bazinet and Layé,
2014; Bosch-bouju and Layé, 2016; Layé et al., 2018). In the
following section, we first describe the receptors which have been
reported to mediate DHA effect in the brain. Then, we focus on
the regulation of the eCB system and the HPA axis as recent data
show that they could mediate the neuroprotective effect of ω3
PUFAs as both are thought to be involved in depression.
Direct Effect of DHA on Specific
Receptors
While free fatty receptors have been widely described to mediate
some of the effects of DHA at the periphery, few reports highlight
a direct effect of DHA through signaling activity in the brain.
In 2000, DHA has been shown to be a ligand of the RXR,
the receptor of retinoic acid (a vitamin A metabolite), which
heterodimerizes with other nuclear receptors such as retinoic
acid receptor, vitamin D receptor, thyroid hormone receptor or
PPAR (Lengqvist et al., 2004). DHA effect on neuritogenesis
does not involve RXR, as its effect in vitro does not activate
RXR (Calderon and Kim, 2007). However, DHA potentiates
retinoic acid effect and improves cognitive symptoms in a
rodent model of Alzheimer disease (Casali et al., 2015) and aged
rodents (Létondor et al., 2016). Interestingly, the loss of RXR
signaling leads to altered emotional and cognitive behavior in
mice (Krzyzosiak et al., 2010; Wietrzych-Schindler et al., 2011).
Importantly, DHA antidepressant effect is absent in RXR knock-
out mice (Wietrzych-Schindler et al., 2011), further highlighting
the role of this receptor and its ligand (possibly DHA and retinoic
acid) in emotional behavior. FFAR, members of the “rhodopsin-
like” GPCR family, namely GPR40 (FFAR1) and GPR120
(FFAR4), have been recently highlighted as potentially mediating
LC FFAs signal from pancreatic beta-cells as well as the intestines
(Itoh et al., 2003; Hirasawa et al., 2005). These lipid receptors were
also reported to be present in the brain (Ma et al., 2007; Dragano
et al., 2017). Memory-induced progenitor cell proliferation and
DHA-induced neurogenesis in the hypothalamus are mediated
by GPR40 (Ma et al., 2008; Yamashima, 2008; Nascimento et al.,
2016). In addition, DHA-induced GPR40 signaling pathway
activates β-endorphin release in the hypothalamus of rodents
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(Nakamoto et al., 2015). Importantly, the chronic activation of
GPR40 signaling in the brain reduces depressive-like behavior
(Nishinaka et al., 2014). In addition, anxiety-like behavior and
sucrose preference, a behavioral sign of anhedonia, are reduced
in GPR40 knock-out mice further highlighting the role of GPR40
signaling in the pathophysiology of mood disorders (Aizawa
et al., 2016). GPR120, another GPR which signals DHA activity,
is highly expressed in the arcuate nucleus of the hypothalamus
and the NAc, a structure involved in emotional behavior (Auguste
et al., 2016). Interestingly, GPR120 activation by a specific
agonist reduces obesity-induced emotional behavior alteration
(Auguste et al., 2016). Taken together, these data suggest that
several receptors could mediate a direct effect of DHA on
neurons to control emotional behavior, opening new avenues in
drug development targeting these receptors. However, additional
studies are needed to determine whether DHA acts through these
receptors to protect from depression and anxiety disorders in
humans.
Endocannabinoid System
Regulation of the eCB system could mediate the neuroprotective
effect of ω3 PUFAs as both are thought to be involved in
depression. The eCB system is in a unique position to link
food lipids, neuroplasticity and behavior (Bazinet and Layé,
2014; Bosch-bouju and Layé, 2016; Chianese et al., 2017). eCBs
are signaling lipids produced from membrane LC fatty acid
in response to neuronal activity and they bind the GPCR
CB1R (Mackie, 2008) (Figure 2). eCBs are produced on-
demand and are rapidly degraded, back into PUFAs or oxidized
into active metabolites (Bosch-bouju and Layé, 2016). eCBs
include the fatty acid AEA, DHEA, oleylethanolamide and
palmitoylethanolamide, as well as 2-AG (Piomelli and Sasso,
2014). The two principal eCBs, AEA and 2-AG, are AA-
derived metabolites, while DHEA is derived from the DHA
and oleylethanolamide and palmitoylethanolamide is derived
from EPA. The most well-studied eCBs are the ω6 PUFA-
derived AEA (Devane et al., 1992) and the 2-AG (Sugiura et al.,
1995) as compared to the ω3 PUFA-derived eCBs. Activation
of CB1 receptors inhibits AC activity leading to a subsequent
reduction in the cAMP cascade, augmentation of potassium
channels, and inhibition of subsequent calcium influx via calcium
channels (Figure 2) (Howlett and Fleming, 1984; Howlett,
2002). Consequently, the activation of the CB1R inhibits the
release of both excitatory (glutamate) and inhibitory GABA
neurotransmitters from presynaptic neurons (Wilson and Nicoll,
2001, 2002; Freund et al., 2003) (Figure 2). Finally, numerous
important studies have unraveled the key role of eCB system
in mood regulation (Morena et al., 2015; Hill and Lee, 2016).
As eCBs are derived from ω6 and ω3 PUFA precursors, we
hypothesized that the effects of PUFAs on mood-related behavior
might be mediated, at least partly, through the eCB system
(Lafourcade et al., 2011; Bosch-Bouju et al., 2016; Manduca
et al., 2017). As such, inadequate PUFAs ratio during critical
time window, i.e., gestation or lactation can lead to changes in
eCBs contents in the brain. Newborn piglets that were fed with
a diet containing ALA, AA and DHA during the first 18 days
of life showed an expected increase of AA and DHA levels
in the brain but also of AEA and DHEA metabolites (Berger
et al., 2001). Watanabe et al. reported that nutritional ω3 PUFAs
deficiency for 2 generations elevates the levels of 2-AG in the
mouse brain while ω3 PUFAs supplementation reduces them.
In this study, DHA brain levels were affected by dietary ω3
PUFAs deficiency, but not AA the precursor of 2-AG which
remained unchanged as compared to the control diet group
(Watanabe et al., 2003). It is now well documented that AA
levels are barely impacted by PUFAs content of the diet while
DHA brain levels are more sensitive to dietary ω6/ω3 PUFAs.
Whether increased 2-AG and AEA after exposure to a diet rich in
ω6 PUFAs is a compensatory effect to buffer AA concentrations
remains to be determined. Lastly a 2-week-supplementation in
DHA increased the DHEA and decreased the AEA in brain
homogenates in both rats and mice (Wood et al., 2010). One
in vitro study also demonstrated that unesterified free DHA
could directly regulate CB1 gene expression in hippocampal
neurons (Pan et al., 2011). Collectively, these reports support
the hypothesis proposing that nutritional PUFAs intake is tightly
linked to brain eCB levels. By regulating levels of eCBs in
the brain, PUFAs have been shown to impact hippocampal
synaptic plasticity (Thomazeau et al., 2017) and eCB-dependent
plasticity (Lafourcade et al., 2011; Manduca et al., 2017) as well
as CB1-associated signaling pathways (Larrieu et al., 2012) in
the PFC and NAc. In mice, perinatal exposure to dietary ω3
PUFA deficiency, which leads to low DHA levels in the PFC
and the NAc, abolished the eCB-long-term depression in these
brain structures. Specifically, this alteration is mediated by an
uncoupling from CB1R to its G protein (Lafourcade et al.,
2011). Moreover, the effect of the CB1 agonist WIN55,212-
2 in anxiety-like behavior was abolished and the CB receptor
signaling pathways were altered in the PFC and hypothalamus
of ω3 PUFA-deficient mice (Larrieu et al., 2012). A recent study
has involved the 2-AG in these aforementioned alterations. Our
recent work highlighted that the inhibition of 2-AG degradation
normalized emotional behavior deficits and eCB-dependent
synaptic plasticity alteration observed in ω3 PUFA-deficient adult
mice (Manduca et al., 2017). These observations are the first
synaptic and molecular evidence that malnutrition related to
ω6/ ω3 PUFAs ratio can have detrimental effect on eCB system,
subsequently leading to impaired behavior.
Hypothalamic–Pituitary–Adrenal Axis
Stress and high trait anxiety are a major risk factor for
neuropsychiatric diseases, particularly major depression and
anxiety disorders, and are etiologically causal in PTSD (Sandi and
Richter-Levin, 2009). Interestingly, although several mechanisms
underlying the effects of dietary ω3 PUFA deficiency on
emotional behavior have been described (e.g., eCB system),
those specifically related to HPA axis function remain poorly
understood. Nevertheless, clinical data reported that low plasma
DHA levels correlate with higher cerebrospinal fluid CRH
levels (Hibbeln et al., 2004) and with higher cortisol in plasma
(Nieminen et al., 2006; Mocking et al., 2013). Healthy men
receiving supplementation for 3 weeks with dietary fish oil
display a blunted cortisol response after an acute mental
stress (Delarue et al., 2003). Mood-related deficits observed in
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FIGURE 2 | PUFAs are key actors in the regulation of endocannabinoid system. Endocannabinoids are signaling lipids produced from membrane long-chain fatty
acid in response to neuronal activity that bind the G-protein-coupled receptor (GPCR) CB1R. The two principal eCBs, AEA and 2-AG, are AA-derived metabolites
while DHEA derived from the DHA. eCBs are released into the synaptic cleft and then bind the CB1R on the presynaptic neuron. Activation of CB1R inhibits adenylyl
cyclase (AC) activity leading to a subsequent reduction in the cyclic adenosine monophosphate (cAMP) cascade, augmentation of potassium channels, and
inhibition of subsequent calcium influx via calcium channels. Consequently, the activation of the CB1R inhibits the release of both excitatory (glutamate) and inhibitory
(GABA) neurotransmitters from the presynaptic neuron and decreases synaptic plasticity. The stimulation of CB1R by CB agonists (THC, WIN55,212-2, and
CP-55940) or eCBs also activate MAPK signaling pathway. Both eCB-dependent plasticity and CB1R-dependent signaling pathway in brain areas involved in
mood-regulation are altered in mice that chronically fed an omega-3 deficient diet.
deficient mice or rats were recently linked to disrupted GR-
mediated signaling pathway, HPA axis hyperactivity as well
as eCB system impairment, all involved in mood regulation
(Ferraz et al., 2011; Lafourcade et al., 2011; Larrieu et al.,
2014, 2015; Bosch-Bouju et al., 2016). Rats that were fed with
a ω3 PUFA deficient diet display HPA axis hyper-reactivity
after stress exposure reflected by increased levels of plasma
corticosterone compared to control diet group (Levant et al.,
2008). Conversely, corticosterone hypersecretion induced by a
chronic stress and IL-1β exposure is dampened in ω3 PUFA
supplemented rats (Song et al., 2003; Ferraz et al., 2011). In
Morgese et al. (2016), increased hypothalamic CRF release
as well as increased plasmatic corticosterone levels has been
shown in ω3 PUFA deficient rats, further demonstrating the
link between HPA axis hyperactivity and dietary ω3 PUFAs. In
a recent study, we demonstrated that anxiety- and depressive-
related behaviors as well as neuronal atrophy in the medial PFC
observed in mice fed with a diet deficient in ω3 PUFAs are
both mediated by HPA axis hyperactivity (Larrieu et al., 2014).
ω3 PUFAs supplementation beyond weaning prevents chronic
stress-induced increases in plasma corticosterone levels (Ferraz
et al., 2011; Larrieu et al., 2014; Meneses et al., 2017), PFC
neuronal shrinkage (Larrieu et al., 2014) as well as anxiety-
and depressive-like behaviors (Ferraz et al., 2011; Larrieu et al.,
2014). In another study, we confirmed and followed up on their
initial observations by demonstrating that GR signaling pathway
is compromised in the PFC of ω3 PUFA-deficient mice along
with dendritic arborization atrophy (Larrieu et al., 2015). The
modulation of neuronal morphology by ω3 PUFAs might be not a
generalized phenomenon since neuronal arborization atrophy is
only observable in the PFC but not the CA1 of the hippocampus
of ω3 PUFA-deficient mice (Delpech et al., 2015b; Larrieu et al.,
2015). To further establish the link between dietary ω3 PUFAs
consumption and neuronal morphology, in vitro studies were
conducted showing that PUFAs activate neurites formation and
growth in hippocampal (Calderon and Kim, 2004; Cao et al.,
2009) and cortical neurons (Cao et al., 2005) in primary culture.
Moreover, in these same cultures, a decrease of DHA leads
to the reduction of the size of neurites (Ikemoto et al., 1997;
Furuya et al., 2002; Calderon and Kim, 2004; Cao et al., 2009).
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The accretion of DHA in the brain considerably facilitates the
formation of the dendritic spines in the hippocampus of Gerbils
that were fed with a diet supplemented in DHA (Sakamoto et al.,
2007). Interestingly, genetically modified Fat-1 mice that are
able to catalyze the conversion of ω6 into ω3 PUFAs display a
higher density of spines in the hippocampus compared to WT
mice (Kang et al., 2004; He et al., 2009). Moreover, increased
spine density in the hippocampus of Fat-1 mice is associated
with better cognitive performances assessed in Morris water
maze along with increased adult neurogenesis (He et al., 2009).
The protective effect of LC ω3 PUFAs could be linked to
hippocampal neurogenesis (recently reviewed in (Zainuddin and
Thuret, 2012). As such, changes in hippocampal neurogenesis
and cell survival in the dentate gyrus have been correlated
with depressive-like behavior. A recent study demonstrated that
clamping glucocorticoid levels prevent CSDS-induced decreases
in neurogenesis and depressive-like behavior in wild type mice,
but not in mice with a genetic ablation of neurogenesis (Lehmann
et al., 2013). This is particularly relevant knowing that LC
ω3 PUFAs supplementation prevents CSDS-induced HPA axis
dysregulation (Larrieu et al., 2014). However, whether the
beneficial effect of ω3 PUFAs on glucocorticoids and mood is
dependent on neurogenesis remains to be evaluated. Finally, an
elegant study showed that EPA but not DHA increases neural
stem cell proliferation reflected by an increased number of
neurospheres bulk via CB1R activity (Dyall et al., 2016). The
findings that ω3 PUFAs alone modulate neuronal arborization as
well as adult neurogenesis highlight the role of PUFAs as a potent
modulator of brain health. Taken together, these studies provide
strong validity of nutritional ω3 PUFA-deficient diet as one of
the many faces of stress that deeply affects GR-dependent HPA
axis function and neuronal morphology plasticity in brain areas
associated with emotional behavior.
Neuroinflammatory Pathways
Inflammation is a key mechanism in the pathophysiology
of mood disorders, including major depression, post-partum
depression and bipolar disorder (Dantzer et al., 2008; Capuron
and Miller, 2011). Increased levels of inflammatory factors, such
as proinflammatory cytokines and chemokines, are found in
a subset of depressed patients and may contribute to their
symptoms through a direct effect in the brain (Raison and
Miller, 2011). The mechanisms underlying inflammation and
depression have been thoroughly reviewed elsewhere (Capuron
and Castanon, 2017). Enhanced peripheral inflammation has also
been reported in PTSD (Gill et al., 2008; Newton et al., 2014;
Passos et al., 2015; Lerman et al., 2016) and bipolar disorder
(Goldstein et al., 2009; Fiedorowicz et al., 2015; Kalelioglu et al.,
2015; Uyanik et al., 2015). Importantly, inflammation has been
proposed to be key in stress vulnerability and the pathogenesis of
major depression (Ménard et al., 2017).
Long chain ω3 PUFAs, DHA, and EPA and their derivatives,
so-called SPMs, are well-known regulators of the inflammatory
response (Serhan, 2014, 2017). More recently, DHA, EPA,
and their derivatives have been shown to also regulate
neuroinflammatory processes (Kavanagh et al., 2004; Li et al.,
2015; Rey et al., 2016; Dong et al., 2017; Fourrier et al., 2017;
Shi et al., 2017; recently reviewed in Layé et al., 2018). Briefly,
the expression of the pro-inflammatory cytokine TNFα, IL-6,
and IL-1β in the brain (triggered by peripheral or intracerebral
administration of LPS, the Gram-negative bacteria endotoxin,
amyloid beta administration or associated to aging) is decreased
by DHA and EPA dietary supplementation (Labrousse et al.,
2012; Orr et al., 2013; Dehkordi et al., 2015; Hopperton et al.,
2016). Importantly, in regards to the protective effect of EPA
in depression, a dietary supplementation with this fatty acid
decreased TNFα expression in the hippocampus following IL-
1β central injection (Dong et al., 2017). In vitro, DHA, and
EPA directly target microglia, the brain innate immune cell
(De Smedt-Peyrusse et al., 2008; Antonietta Ajmone-Cat et al.,
2012; Pettit et al., 2013; Chang et al., 2015; Fourrier et al.,
2017), however, a direct effect of these fatty acids on microglia
in vivo has not been studied yet. In a model of multiple
sclerosis induced by cuprizone, DHA/EPA promote the shift
of microglia polarization toward a repair non-inflammatory
phenotype (Chen et al., 2014). We have found that the
brain content of ω3 PUFA, either increased through the diet
or by genetic means, influences microglia and the related
neuroinflammatory response to LPS (Mingam et al., 2008;
Madore et al., 2014; Delpech et al., 2015a,b; Dinel et al.,
2016). In rodent models of neuroinflammation triggered by the
intracerebral administration of amyloid-β or cuprizone, brain
DHA decreases the number of activated microglia, but not
of astrocytes (Hopperton et al., 2016), and promotes an anti-
inflammatory phenotype of microglia (Chen et al., 2014). An
acute intravenous administration of DHA reduces LPS-induced
cytokine production in the hippocampus (Fourrier et al., 2017),
but no significant effect of intravenously administered DHA was
shown on microglia activation (measured by the upregulation
of translocator protein TSPO by Positron-emission tomography)
in the injured spinal chord of rat (Tremoleda et al., 2016).
DHA and EPA effect on neuroinflammatory pathways could be
either direct or indirect. Indeed, LC-PUFAs are converted by
COX, LOX, and CYP450 into SPMs, which display pro or anti-
inflammatory activities (Chiang and Serhan, 2017), including
in the brain (Orr et al., 2013; Rey et al., 2016; Layé et al.,
2018). Eicosanoids, resolvins, protectin and maresin derived
from DHA and EPA have anti-inflammatory and pro-resolving
activities (Bazan, 2009; Serhan et al., 2011). On the opposite,
SPMs derived from LA and AA (prostaglandins, leukotrienes
or thromboxanes) are mostly pro-inflammatory (Calder, 2006).
In vitro, DHA derivatives display anti-inflammatory activities
in microglia (Marcheselli et al., 2003; Lukiw et al., 2005; Orr
et al., 2013; Rey et al., 2016). Brain inflammation triggered by the
administration of LPS activates ω6 PUFA derived-prostaglandins
production in the brain (Rosenberger et al., 2004; Taha et al.,
2017), together with the expression of the enzymes involved in
the synthesis of SPMs (Rosenberger et al., 2004; Taha et al.,
2017). However, recent work showed that amyloid-β brain
infusion, which is proinflammatory, did not increase brain SPMs
production (Hopperton et al., 2018). Importantly, PUFAs dietary
intervention can modulate cellular levels of both PUFAs and
SPMs, with dietary ω6 PUFAs supplementation increasing AA-
derived and decreasing EPA-derived SPMs (Taha et al., 2016).
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Conversely, LC ω3 PUFAs supplementation increasing EPA and
DHA-derived SPMs (Balvers et al., 2012; Hashimoto et al., 2015)
have not been consistently demonstrated (Hopperton et al.,
2018). These observations reinforce the need for more studies to
link nutritionnal interventions and SPMs production in specific
brain regions.
As previously described, clinical trials using DHA and/or EPA
showed mixed results on depressive symptoms. However, based
on meta-analysis, EPA has been suggested as a predictor of mood
disorder treatment efficiency (Martins, 2009; Sublette et al., 2011;
Mocking et al., 2016). Such a positive effect of EPA could be
linked to its anti-inflammatory activity. Indeed, in depressed
patients, high EPA supplementation is more effective in those
with inflammation (Rapaport et al., 2016). In particular, patients
with high IL-1 receptor antagonist and C-reactive protein blood
levels have greater improvement in mood symptoms in response
to EPA, but not DHA enriched dietary supplement. Additional
studies with a higher number of patients are warranted to confirm
this interesting first study. In addition, whether the higher
efficiency of high EPA rather of DHA dietary supplementation
is linked to its specific effect on inflammation through specific
SPMs remains to be investigated.
CONCLUSION AND FUTURE
DIRECTIONS
As indicated above, the summarized literature indicate that
low ω3 PUFAs intake may predispose certain individuals to
depression and anxiety and that dietary supplementation with
LC ω3 PUFAs represents an interesting strategy for preventing or
treating depression and anxiety disorders in certain individuals.
However, several important issues remain to be determined.
One of those is the discordant results regarding outcomes in
clinical nutritional interventions to investigate the effectiveness
of ω3 PUFA supplementation on mood. The unmatched results
seem to be partly due to the lack of standardization regarding
important parameters such as (i) the inclusion criteria used,
(ii) the PUFA composition of the fish oil as well as (iii) the
nutritional baseline status of subjects, and (iv) the methods
of diagnosis used. We are now beginning to understand how
PUFAs affect our brain through a direct sensing effect or an
indirect one. This review highlights that ω3 PUFAs, in particular
DHA, act onto the brain through a direct effect on FFAR or
other indirect mechanisms. We also discussed an indirect effect
of ω3 PUFAs on eCB and the HPA axis systems as relevant
mechanisms by which dietary ω3 PUFAs modulate mood-related
behaviors. Although recent work suggest a causal relationship
between nutritional ω3 PUFAs deficiency and alterations of
these two systems, major questions remain unanswered, such
as how dietary ω3 PUFA maintains HPA axis function to
prevent emotional impairment. In this review, we highlighted
how powerful dietary PUFAs are in the modulation of the
eCB system, which is known to be intimately involved in
the regulation of the HPA axis (McLaughlin et al., 2014). As
to whether these two mechanisms are interconnected in the
effects of ω3 PUFA deficiency-induced depression is yet to be
determined. In conclusion, this review reinforces the idea of the
usefulness of the dietary ω3 PUFAs as an interesting tool for
the design and testing of new non-pharmacological strategies in
the treatment of neuropsychiatric disorders such as mood-related
disease.
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